Sector & Market
Inhibrx Shares Jump >20% on Merger Interest
Inhibrx Biosciences stock surged over 20% after Reuters reported takeover interest from Merck, Merck KGaA, and Ono Pharmaceutical.
The interest focuses on INBRX-106, being tested alone and with Merck’
